The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.

Side by side

Compound comparison

Check interactions →Open as saved/share list

NAD+/NMN

OTC · Grade C

Goals
longevity, mitochondria
Evidence
10 RCT / 5 animal / 4 in vitro
Routes
oral, injectable-sc
WADA
No
FDA
Not approved
Cancer caution
caution
Typical dose
—
Half-life
—
Primary mechanism
NAD+ pool replenishment
View full report →

Humanin

Research chemical · Grade C

Goals
cognition, longevity, mitochondria
Evidence
0 RCT / 0 animal / 0 in vitro
Routes
injectable-sc
WADA
S4
FDA
Not approved
Cancer caution
hard-stop
Typical dose
—
Half-life
—
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

J-147

Research chemical · Grade C

Goals
cognition, longevity, mitochondria
Evidence
1 RCT / 5 animal / 4 in vitro
Routes
oral
WADA
S4
FDA
Not approved
Cancer caution
caution
Typical dose
—
Half-life
—
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

L-Glutathione

Research chemical · Grade C

Goals
mitochondria, immune, longevity, beauty
Evidence
5 RCT / 0 animal / 0 in vitro
Routes
topical, oral
WADA
No
FDA
Not approved
Cancer caution
none
Typical dose
—
Half-life
Community practice: split doses morning and evening for GlyNAC given the ~6 hour plasma half-life of NAC
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →